Author/Authors :
Amedeo A. Failli، نويسنده , , Jay S. Shumsky، نويسنده , , Robert J. Steffan، نويسنده , , Thomas J. Caggiano، نويسنده , , David K. Williams، نويسنده , , Eugene J. Trybulski، نويسنده , , Xiaoping Ning، نويسنده , , Yeungwai Lock، نويسنده , , Tarak Tanikella، نويسنده , , David Hartmann، نويسنده , , Peter S. Chan، نويسنده , , C.H. Park، نويسنده ,
Abstract :
Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.
